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BACKGROUND: Familial breast cancers are known to be of early onset. This article provides differences in the age of onset of breast
cancer and death by breast cancer between women with and without a family history.
METHODS: The Swedish Family-Cancer Database was used to estimate the cumulative risk of breast cancer and death by breast cancer
according to family history with a stratified Cox model. Family history was defined separately for affected mother or sister considering
their diagnostic ages.
RESULTS: The age to reach the same cumulative incidence as women without family history decreased with decreasing diagnostic age
of the affected relative. Women with a maternal history reached the risk of women lacking a family history at the age of 50 years
between 12.3 (mother affected o40 years) and 3.3 years (mother affected 482 years) earlier. The trend for breast cancer mortality
was essentially similar.
CONCLUSIONS: Women with mother or sister affected by breast cancer are diagnosed and die at earlier ages than do women without
family history. The differences depend on the diagnostic age of the affected relative. The present data may provide a rationale to
derive recommendations for the starting age of screening in women with affected family members.
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A family history of female breast cancer is associated with an
increase in the risk of breast cancer in first-degree female relatives
by about two-fold, but the magnitude of risk depends on a number
of factors, such as diagnostic age (Collaborative Group on
Hormonal Factors in Breast Cancer, 2001; Hemminki et al,
2008b). Familial risk has been included in clinical risk estimation
models for breast cancer (Gail et al, 1989; Claus et al, 1994; Tyrer
et al, 2004), but the manner in which it could be translated into
recommendations for a surveillance strategy for at-risk women
requires scientific justification (Smith et al, 2004, 2006; Saslow
et al, 2007). The guidelines for breast cancer screening of average-
risk individuals were based on trials investigating mortality
reduction by cancer screening, and the starting age was
determined by the onset of breast cancer incidence (IARC,
2002). Although familial breast cancers are known to be of early
onset (Claus et al, 1990; Collaborative Group on Hormonal Factors
in Breast Cancer, 2001; Hemminki et al, 2008b), data have not been
accurate enough to provide a scientific basis for the existing
recommendations for the time of implementation of screening
methods (Smith et al, 2004). The recommendations for at-risk
women emphasise breast cancer diagnosis in relatives before the
age of 50 years, thereby leaving open the question about breast
cancer in older women.
The aim of this study was to assess (1) the cumulative incidence
and risk of death from breast cancer in women with a family
history of breast cancer compared with those without a family
history of breast cancer and (2) the impact of the relative’s age at
diagnosis on the diagnostic age. We used the nation-wide Swedish
Family-Cancer Database to estimate the cumulative incidence of
breast cancer and the cumulative risk of death by breast cancer in
women with a family history of breast cancer, compared with those
lacking a family history. Family history was defined separately for
an affected mother or sister considering their diagnostic ages. The
results may encourage appropriate future analysis to derive
recommendations for the starting time of screening in women
with an affected family member.
MATERIALS AND METHODS
The Swedish Family-Cancer Database was created in the 1990s
by linking information from the Multigeneration Register, national
censuses, Swedish Cancer Registry and death notifications
(Hemminki et al, 2001). Data on family relationships were
obtained from the Multigeneration Register, in which all
individuals born in or after 1932 are registered with their biolo-
gical parents as families; in addition, data on immigrants were
included. Thus, the individuals in the Database can be divided into
offspring generation (individuals born in or after 1932) and
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sparental generation. The nation-wide Swedish Cancer Registry was
established in 1958 and reached complete coverage in 1961. It is
based on compulsory reports of diagnosed cases, with coverage of
cancer registration close to 100% (Centre for Epidemiology, 2005).
The 2006 update of the Database includes more than 11.5 million
individuals and cancer cases from years 1958 to 2004 and the
underlying cause of death until 2003 (Hemminki et al, 2006).
Further details on the Database are described elsewhere
(Hemminki et al, 2001, 2006). The cancers in the Database are
coded according to the 7th International Classification of Diseases
(ICD-7). Breast cancer in this study refers to first primary invasive
breast cancer (ICD-7 code 170). The study population consisted of
women from the offspring generation with two identified parents,
in total 3.6 million women. Women without identified parents,
who were mostly immigrants, were excluded from the study. The
age structure of the Database (children born after 1932) implicates
that the maximum age of diagnosis of affected sisters is 72 years;
the age of mothers was not limited.
Women with mother or sister affected by breast cancer were
defined to be at familial risk. Here, the register-based definition
of family history was used, that is, family history was defined
independently of the maternal or sororal diagnostic date.
Cumulative risks of breast cancer and death due to breast cancer
according to family history were estimated using a stratified Cox
model based on Tsiatis’ method (Tsiatis, 1981) (PROC PHREG;
SAS version 9.1; SAS Institute, Cary, NC, USA). The strata were
defined according to the disease status of the mother or sister and
according to their diagnostic ages. Women with multiple affected
relatives were analysed separately. Individuals entered the risk
period at birth, at immigration date, or at first year of the study
(1961). Immigrants might have had breast cancer diagnosed in
their country of origin; however, the median age at immigration
for immigrants in the Database was below 30 years. For analysis of
the age of diagnosis with breast cancer, the censoring events were
death, emigration, 31 December 31 2004, absence at census and
diagnosis of malignancy at sites other than breast. Women were
also censored at diagnosis of malignancy at sites other than breast,
because their risk afterwards might be different from the risk in
the general population. For the analysis of the age of death from
breast cancer, censoring events were the same, but ‘death’ was
replaced by ‘death from another cause than breast cancer’.
Socioeconomic status, calendar period, age at first birth, number
of children and region were taken into account as covariates.
Socioeconomic status was based on the Swedish socioeconomic
classification, which relies primarily on occupation (Statistics
Sweden, 1982). In this study, categories ‘Farmer’, ‘Blue collar
worker’, ‘White collar worker’, ‘Private’, ‘Professional’ and ‘Other/
unknown’ were used. The categories of regions were ‘Big cities’,
‘South Sweden’, ‘North Sweden’ and ‘Unknown’. This categorisa-
tion was chosen because screening behaviour might differ between
residents of these regions. For example, the proportion of women
taking part in screening might be lower in North Sweden because
of longer distances to the nearest screening centre. The socio-
economic index and region were determined at the event time or
censoring time, respectively. We calculated the age at which the
cumulative risks for women with an affected mother or sister
reached the cumulative risk of women without a family history at
the age of 40 or 50 years (Lai and Su, 2006).
RESULTS
Table 1 presents the number and median age according to family
history for all women from the study population, for women
diagnosed with breast cancer and for women who died from breast
cancer.
Figure 1 shows the cumulative incidence of breast cancer
(Figure 1A) and the cumulative risk of death by breast cancer
(Figure 1B) according to the type of family history (no family
history, mother affected, sister affected). The cumulative incidence
of breast cancer was almost equally high for women with an
affected mother or sister; the familial incidence was almost two
times higher than the incidence for women lacking a family
history. We marked in Figure 1A the cumulative incidence (1.7%)
reached by women lacking a family history at the age of 50 years.
Women with a sororal history reached this cumulative incidence
5.4 years earlier; women with a maternal history reached this
incidence 4.7 years earlier. At the age of 40 years, the cumulative
incidence of women lacking a family history was 0.36%. This
incidence was reached 3.7 years earlier by women with a sororal
Table 1 Number and median age of women in the whole study population, women diagnosed with breast cancer and women died from breast cancer
according to family history
Study population Women diagnosed with breast cancer Women died from breast cancer
Family history No.
Median age at censoring
or diagnosis (years) No.
Median age at
diagnosis (years) No.
Median age
at death (years)
No family history 3480260 32 36835 51 4793 53
Mother affected 120108 46 3649 50 452 51
0–39 years 6428 27 88 39 20 42
40–49 years 23168 34 381 45 42 47
50–59 years 31728 40 715 48 81 49
60–72 years 37029 49 1316 50 164 52
73–82 years 16360 57 829 51 109 53
482 years 5395 60 320 54 36 55
Sister affected 31000 57 1780 52 228 52
0–39 years 3331 48 140 46 23 43
40–49 years 10228 54 534 51 71 51
50–59 years 12138 58 760 52 99 53
60–72 years 5303 61 346 54 35 56
Sister+mother affected 2794 56 252 49 27 53
Two sisters affected 925 58 76 51 12 55
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shistory and 4.0 years earlier by women with a maternal history. In
Figure 1B, the cumulative risk of breast cancer death is shown. For
women lacking a family history, mortality at the age of 40 years
was 0.05% and that at the age of 50 years was 0.22%. These
mortalities were reached 4.4 years and 7.3 years earlier,
respectively, by women with a sororal history. Women with a
maternal history reached these mortalities 4.2 years and 4.8 years
earlier, respectively.
Table 2 (top part) shows the ages at which women with a
maternal or sororal history of breast cancer reach the cumulative
incidence of 1.7% for breast cancer, that is, the risk that women
without a family history reached by the age of 50 years (see
Figure 1), according to the diagnostic age of the affected family
member. The age difference at diagnosis due to family history is
shown by ‘AD’, which decreased from 12.3 years when the mother
was diagnosed at age below 40 years to 3.3 years when she was
diagnosed at age over 82 years. The age difference for sisters
decreased from 8.9 years (sister diagnosed before the age of 40
years) to 3.0 years (sister diagnosed between 60 and 72 years). Data
for age differences in mortality are shown in Table 2 (bottom part).
There were few fatal events but the trend was essentially similar to
the incidence data: diagnosis at an early age in one family member
also predicted an early death of the second family member.
Table 3 shows the ages at which women with a maternal or
sororal history of breast cancer reach the cumulative incidence of
0.36% for breast cancer, that is, the risk that women without a
family history reached by the age 40 of years (see Figure 1),
according to the diagnostic age of the affected family member. The
age difference at diagnosis due to family history decreased from
9.5 years when the mother was diagnosed at an age below 40 years
to 0.8 years when she was diagnosed at an age over 82 years. The
age difference for sisters decreased from 7.0 years (sister diagnosed
before the age of 40 years) to 0.9 years (sister diagnosed between
60 and 72 years). Fatal events were too few for a detailed analysis.
Women with an affected mother and sister, and women with
more than one affected sister were considered separately (data not
shown). The numbers of women affected by breast cancer in these
groups were small. For women with a mother and a sister affected,
the ages to reach the same risk as the general population at the age
of 50 and 40 years were 41.3 years (33 cases until this age, 95%
confidence interval (CI): 39.2–43.1 years) and 32.8 years (7 cases,
95% CI: 31.4–36.3 years), respectively. The corresponding ages for
women with two affected sisters were 42.3 years (11 cases, 95% CI:
33.4–44.9 years) and 25.8 years (2 cases, 95% CI: 23.3–38.1 years),
respectively. The numbers of deaths in women with a mother and a
sister affected (27) or with two affected sisters (12) were too small
for a separate analysis.
DISCUSSION
Our results provide initial data on the age of onset of familial
cancer estimated with a large population-based data set. For
example, if the general starting age of mammography screening is
defined to be 50 years, our data show that the same cumulative
risk is reached 9–12 years earlier for women with a mother or a
sister affected by breast cancer before 40 years. According to
previous recommendations, an earlier start of screening is not
recommended for women with mother or sister who was affected
older than 50 years. However, the present results indicated that
these women are at an increased risk. The estimation of
the age at which familial cases reached the risk of death in
women without a family history permitted essentially identical
conclusions, even though the results were based on a smaller
numbers of events.
The American Cancer Society recommends average-risk women
begin mammography screening at the age of 40 years (Smith et al,
2007). In the European Union, the Advisory Committee on Cancer
Prevention recommends the introduction of organised mammo-
graphy screening beginning at 50 years (Advisory Committee on
Cancer Prevention, 2000). In most nationally organised pro-
grammes in Europe and Canada, the starting age of mammography
screening is 50 years (IARC, 2002). These screening programmes
do not take the family history of breast cancer into consideration,
although some guidelines recommend individual strategies when
risk factors are present (Albert and Schulz, 2004). The National
Board of Health and Welfare recommends Swedish counties to
offer mammography screening for women at the age of 40–74
years. There are differences between counties when they start
screening and the screening interval (Olsson et al, 2000). The
American Cancer Society recommends MRI (magnetic resonance
imaging) screening as an adjunct to mammography screening for
women with an estimated 20–25% or greater lifetime risk of breast
cancer (Saslow et al, 2007). However, the starting age of screening
for breast cancer in women at increased risk is not well established.
The National Center for Clinical Excellence in the United Kingdom
recommends annual mammography screening for at-risk women
beginning at the age of 40 years, which is 10 years earlier than the
recommended starting age in the United Kingdom for the general
population (McIntosh et al, 2004); the increased risk is defined as
an estimated lifetime risk of breast cancer between 17–30%, which
includes women with a first-degree relative affected by breast
cancer before 50 years and women with two affected first- or
second-degree relatives (McIntosh et al, 2004). The American
Cancer Society recommends women with a relative affected by
breast cancer before 50 years, with two or more relatives affected
by breast cancer and with a relative affected by two independent
breast cancers to start 10 years earlier than average-risk women, or
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Figure 1 Cumulative incidence of breast cancer and cumulative risk of
death by breast cancer according to the type of family history. (A) Age at
which women with a family history reach the cumulative risk of women
lacking a family history at the age of 40 and 50 years for incidence. (B) Age
at which women with a family history reach the cumulative risk of women
lacking a family history at the age of 40 and 50 years for death from breast
cancer.
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s5–10 years earlier than the youngest patient in the family (Smith
et al, 2003).
The rationale of mammography screening is the reduction of
mortality by breast cancer. As evidence of an impact of family
history on the survival of breast cancer patients in general is
lacking (Chappuis et al, 1999; Hemminki et al, 2008a), the
cumulative risk of death by familial breast cancer is increased
because of the increased incidence. The difference in the age of
onset of familial cases might be influenced by overdiagnosis or an
earlier detection of familial cases because of increased surveillance
of familial cases: women with a close relative affected by breast
cancer may participate in cancer screening more often, more
frequently or earlier than women in the general population (Shah
et al, 2007). The likelihood of lead-time bias motivated us to
investigate the difference in breast cancer-specific mortality
between women with and without affected relatives. The present
data showed essentially the same differences in age of diagnosis
and age of death between women with and without affected
relatives. Thus, lead-time bias does not seem to influence the
difference in the onset age of breast cancer in familial and non-
familial cases. This is in agreement with earlier results that showed
at most a minor influence of screening (Bermejo and Hemminki,
2005; Hemminki and Bermejo, 2005).
This study includes the whole Swedish population up to the age
of 72 years and their parents. The information on cancer and
diagnostic ages was registered data. Thus, an important advantage
was the accuracy and completeness of the analysed data, which
minimised biases related to over- and under-reporting of family
history, selection and recall. The existing recommendations for
surveillance of women at increased risk are mainly based on expert
opinion, with support from the assessment of breast cancer risk
with statistical models (Gail et al, 1989; Claus et al, 1994; Tyrer
et al, 2004) or epidemiological studies (Smith et al, 2003; McIntosh
et al, 2004). Different models for the prediction of breast cancer
risk have been developed. These models include different
combinations of risk factors. In the past, the most widely used
models were the Gail model and the Claus model (Gail et al, 1989;
Claus et al, 1994). The Gail model takes the number of affected
first-degree relatives, age at menarche, age at first birth and the
number of breast biopsies into account (Gail et al, 1989). This
model does not consider the age at diagnosis and includes only
first-degree relatives (Evans and Howell, 2007). The Claus model
predicts lifetime risk of breast cancer for different combinations of
affected first- and second-degree relatives (Claus et al, 1994).
However, it does not include risk factors other than family history
and it reflects the risk of breast cancer for women in the United
States in the 1980s (Evans and Howell, 2007). The BRCAPRO
model predicts breast cancer risk on the basis of the probability of
carrying a mutation in BRCA1/2, taking cancer status and age of
first- and second-degree relatives into account (Parmigiani et al,
1998). This model includes only BRCA1/2 as genetic elements
(Evans and Howell, 2007). The Breast and Ovarian Analysis of
Table 2 Age at which women with a family history reach the cumulative risk of women lacking a family history at age 50 years for incidence (top) and for
death (bottom) considering the diagnostic age of the relative
Maternal history Sororal history
Diagnostic age of
relative (years) No.
a Age
b (years) 95% CI AD
c No.
a Age
b (years) 95% CI AD
c
First breast cancer
0–39 36 37.7 36.9 40.0  12.3 38 41.1 38.4 43.5  8.9
40–49 158 43.3 42.2 44.2  6.7 126 44.5 43.6 45.7  5.5
50–59 264 44.7 43.8 45.6  5.3 146 44.8 44.1 46.1  5.2
60–72 429 46.0 45.4 46.8  4.0 62 47.0 45.6 48.9  3.0
73–82 214 46.1 45.2 46.9  3.9
482 66 46.7 45.3 48.0  3.3
Death by breast cancer
0–39 6 35.4 34.3 40.8  14.6 9 38.3 32.5 42.6  11.7
40–49 29 45.3 41.8 47.8  4.7 31 44.5 42.3 46.8  5.5
50–59 49 45.0 42.8 46.8  5.0 32 43.9 39.4 47.4  6.1
60–72 81 45.3 43.5 48.2  4.7 12 49.7 37.4 56.3  0.3
73–82 48 45.3 41.8 47.5  4.7
482 6 42.8 29.8 52.7  7.2
Abbreviations: AD¼age difference; CI¼confidence interval.
aNumber of cases until (Age).
bAge to reach the same cumulative risk as women lacking a family history at age 50.
cDifference between and ‘Age’ and 50 years.
Table 3 Age at which women with a family history reach the cumulative risk of women lacking a family history at age 40 years for incidence considering
the diagnostic age of the relative
Maternal history Sororal history
Diagnostic age of
relative (years) No.
a Age
b (years) 95% CI AD
c No.
a Age
b (years) 95% CI AD
c
0–39 10 30.5 28.2 33.5  9.5 8 33.0 28.4 35.1  7.0
40–49 45 33.7 33.1 35.1  6.3 24 35.2 33.6 37.7  4.8
50–59 75 35.4 34.2 36.8  4.6 28 38.1 36.5 39.0  1.9
60–72 97 37.3 36.4 38.1  2.8 11 39.1 37.1 41.8  0.9
73–82 41 38.6 36.5 40.1  1.4
482 12 39.3 35.3 41.2  0.8
Abbreviations: AD¼age difference; CI¼confidence interval.
aNumber of cases until (Age).
bAge to reach the same cumulative risk as women lacking a family history at age 40.
cDifference between ‘Age’ and 40 years.
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sDisease Incidence and Carrier Estimation Algorithm (BOADICEA)
model includes a polygenic component for breast cancer suscept-
ibility in addition to BRCA1/2 (Antoniou et al, 2004). The Tyrer–
Cuzick model combines the prediction of genetic risk based on
family history information and personal risk factors (Tyrer et al,
2004). This study presents empirical risk estimates on the age of
onset based on breast cancers in first-degree relatives taking the
relative’s diagnosis age into account. Second-degree relatives were
not considered because the structure of the Swedish Family-Cancer
Database implies that identification of grandparents and aunts is
only possible for women whose parents were born in 1932 or later,
that is, only for women who were aged B50 years or less at the end
of the study.
The efficacy of screening is not equivalent to case detection.
There is ample evidence that the efficacy of mammography
screening in average-risk women is lower in women aged 40–49
years than in those aged 50–69 years (IARC, 2002; Moss et al,
2006). No evidence has been found for the efficacy of screening
under the age of 40 years. However, it has been shown that
women with an increased genetic risk of breast cancer might
benefit from an intensified surveillance, which includes an earlier
start of mammography screening, expert clinical breast exami-
nation and teaching of ‘breast awareness’ (Moller et al, 1999).
Further research is required to clarify the efficacy of breast cancer
screening before 50 and 40 years in women at increased risk of
breast cancer.
We conclude that women with mothers or sisters affected by
breast cancer were diagnosed at earlier ages than were individuals
without a family history. The differences in age of onset depended
on the age of affected relatives, whereas the type of proband
(mother or sister) seemed to have a minor function. Under the
discussed limitations, the present data should encourage further
analysis in order to derive evidence-based recommendations for
the starting age of screening in women with a family history of
breast cancer.
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